Study: Moderna, Merck vaccines could cut melanoma's recurrence by 44 percent


There could be light at the end of the tunnel for individuals battling melanoma cancer. CBS News reported that researchers conducted a study to develop a "potential skin cancer vaccine" from Merck and Moderna, and found some promising results.
According to Reuters, a combination of Moderna's experimental melanoma vaccine and Merck's immunotherapy Keytruda "cut the risk of skin cancer's recurrence or death by 44 percent compared with Keytruda alone in a mid-stage trial."
Moderna's trial shot uses the same mRNA vaccine technology that has played an integral role in the success of COVID-19 vaccines, and the combination with Keytruda "has the capacity to be a new paradigm in the treatment of cancer," Paul Burton, Moderna's chief medical officer said in an interview.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There were 157 melanoma patients involved in the ongoing clinical trial, and researchers noted side effects in 14.4 percent of the patients who received the drug-vaccine combo compared to 10 percent of people who were only administered Keytruda, writes Reuters.
CBS notes that the shares of both the pharmaceutical and biotech companies increased on Tuesday after researchers reported a positive outcome of the shots midway through the study.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kelsee Majette has worked as a social media editor at The Week since 2022. In 2019, she got her start in local television as a digital producer and fill-in weather reporter at NTV News. Kelsee also co-produced a lifestyle talk show while working in Nebraska and later transitioned to 13News Now as a digital content producer.
-
August 31 editorial cartoons
Cartoons Sunday’s political cartoons include FEMA's new scheme, Gavin Newsom's antics, and a clue in the Epstein files
-
Disarming Hezbollah: Lebanon's risky mission
Talking Point Iran-backed militia has brought 'nothing but war, division and misery', but rooting them out for good is a daunting and dangerous task
-
Woof! Britain's love affair with dogs
The Explainer The UK's canine population is booming. What does that mean for man's best friend?
-
SpaceX breaks Starship losing streak in 10th test
speed read The Starship rocket's test flight was largely successful, deploying eight dummy satellites during its hour in space
-
Rabbits with 'horns' sighted across Colorado
speed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's study
Speed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-off
Speed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet undersea
Speed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
-
Bacteria can turn plastic waste into a painkiller
Under the radar The process could be a solution to plastic pollution
-
Scientists want to regrow human limbs. Salamanders could lead the way.
Under the radar Humans may already have the genetic mechanism necessary
-
New York plans first nuclear plant in 36 years
Speed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes